廣東東陽光藥業股份有限公司 章程 公司、韶關前海熙正產業發展基金企業（有限合夥）、蘇州中金上汽新興產業股權 投資基金合夥企業（有限合夥）、珠海康普股權投資合夥企業（有限合夥）、建信金 融資產投資有限公司、廣東東陽光科技控股股份有限公司、杭州中合國信壹號股 權投資基金合夥企業（有限合夥）、深圳市東陽光實業發展有限公司共同作為發起 人，通過廣東東陽光藥業有限公司整體變更為股份有限公司的方式設立；在東莞 市市場監督管理局註冊登記，取得營業執照。 廣東東陽光藥業股份有限公司章程 第一章 總則 第一條 為規範廣東東陽光藥業股份有限公司（以下簡稱「公司」或「本公 司」）的組織和行為，保護公司、股東和債權人的合法權益，根據《中華人民共 和國公司法》（以下簡稱「《公司法》」）、《中華人民共和國證券法》（以下簡稱「《證 券法》」）、《境內企業境外發行證券和上市管理試行辦法》（以下簡稱「《試行辦 法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「《香港聯交所上市規 則》」）和其他有關法律、法規規定並參照《上市公司章程指引》（以下簡稱「《章程 指引》」），制定本章程。 第二條 公司系依照《公司法》和其他有關規定，由廣東東 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本聯合公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 廣東東陽光藥業股份有限公司 宜昌東陽光長江藥業股份有限公司 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO ., LTD . （ 在中華人民共和國註冊成立之股份有限公司 ） （股份代號：1558） 聯合公告 撤銷H股上市地位及 撤銷上市地位的預期時間表及 實行換股 要約人的財務顧問 本聯合公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約，亦 非在任何司法管轄區招攬任何投票或批准。 本聯合公告不會在構成違反任何司法管轄區相關法律的情況下於或向有關司法管 轄區發佈、刊發或派發。 SUNSHINE LAKE PHARMA CO ., LTD . （ 一間於中華人民共和國註冊成立的有限公司 ） 本公司的財務顧問 緒言 茲提述(i)宜昌東陽光長江藥業股份有限公司（「本公司」）於二零二四年三月八 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) is set to list on the Hong Kong Stock Exchange on August 7, aiming to integrate its R&D capabilities with Dongyang Sunshine Changjiang Pharmaceutical's national sales network, creating a closed loop of R&D, production, and sales to accelerate global operations and drive value reconstruction [1][2]. Group 1: Market Expectations and Valuation - The market anticipates that Dongyang Sunshine Pharmaceutical's valuation post-listing could exceed HKD 50 billion, driven by the integration of its innovative drug assets and the overall revaluation of the innovative drug sector this year [1][2]. - The innovative drug sector has seen a significant revaluation and value release, reflecting heightened market confidence and attention, with Dongyang Sunshine Pharmaceutical's integrated model forming a crucial basis for its core value reassessment [1][2]. Group 2: Product Pipeline and Commercial Potential - Dongyang Sunshine Pharmaceutical boasts a robust pipeline of high-potential innovative drugs, with three original innovative drugs already launched and 49 in development, including one nearing market entry and ten in clinical phases II and III [2]. - Key products include Ifenprodil, the first domestic drug in III clinical trials for IPF, and insulin products with significant market potential in the U.S., where the insulin market exceeds USD 10 billion [2]. - The company has several projects with potential authorization values exceeding USD 1 billion, indicating substantial commercial value release from its expanding product pipeline [2].

（ 一間於中華人民共和國註冊成立的有限公司 ） 廣東東陽光藥業股份有限公司 宜昌東陽光長江藥業股份有限公司 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO ., LTD . （ 在中華人民共和國註冊成立之股份有限公司 ） （股份代號：1558） 香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本聯合公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 本聯合公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約，亦 非在任何司法管轄區招攬任何投票或批准。 本聯合公告不會在構成違反任何司法管轄區相關法律的情況下於或向有關司法管 轄區發佈、刊發或派發。 SUNSHINE LAKE PHARMA CO ., LTD . 有關特別股息之聯合公告 要約人的財務顧問 本公司的財務顧問 – 1 – 緒言 茲提述(i)宜昌東陽光長江藥業股份有限公司（「本公司」）於二零二四年三月八日根 據收購守則規則3.7刊發的 ...

Core Viewpoint - Dongyangguang Group is entering a new development stage with the upcoming IPO of Dongyangguang Pharmaceutical, marking a significant step in China's innovative pharmaceutical sector [1][5]. Group Overview - Established 28 years ago, Dongyangguang Group has grown from scratch to a private enterprise with over 30,000 employees and assets exceeding 80 billion yuan, becoming a leader in multiple industries including electronic new materials, biomedicine, and health care [1][2]. - The company has successfully cultivated two publicly listed companies with market capitalizations in the hundred billion range [1]. Industry Development - The group is actively expanding into the artificial intelligence and robotics sectors, recognizing the potential of AI as a new engine for high-quality development [2][3]. - Dongyangguang has established a complete fluorine and chlorine chemical industry chain, positioning itself as the only company in South China with such capabilities [4]. Pharmaceutical Sector - Dongyangguang Pharmaceutical has 150 globally approved drugs and over 100 in the pipeline, aiming to become a leading pharmaceutical enterprise in China and globally [5][6]. - The company has established a robust R&D system and has been recognized for its innovation, winning multiple awards and holding over 2,500 patents [6][11]. Health and Wellness Industry - The company has pioneered the ecological breeding of Cordyceps sinensis, achieving significant production milestones and aiming for an annual output of 100 tons with sales exceeding 10 billion yuan [7][8]. - Dongyangguang is developing a product matrix around Cordyceps, targeting the burgeoning health and wellness market [8]. Innovation and Internationalization - The group emphasizes innovation and internationalization as core strategies, having built a strong R&D platform and established a global sales network covering eight countries [9][12]. - Dongyangguang has made significant investments in R&D, including collaborations with international experts and institutions to enhance its competitive edge [11][12]. Social Responsibility - Dongyangguang Group has committed over 500 million yuan to public welfare and has created over 10,000 job opportunities, reflecting its dedication to social responsibility [14].

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and officially launched the first case of "H-share absorption merger privatization + introduction listing" in the Hong Kong market [1] - The company plans to list on the Hong Kong Stock Exchange on August 7 under the name "Dongyangguang Pharmaceutical" (06887), creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows Dongyangguang Pharmaceutical to issue H-shares to minority shareholders of its subsidiary Dongyangguang Changjiang Pharmaceutical, facilitating overall listing [1] Group 2 - Industry insiders note that this move breaks traditional capital operation time barriers, reduces friction costs in acquisitions, and effectively safeguards shareholder rights [1] - The listing is seen as a response to the national strategy of optimizing capital market structure and provides a reference model for industrial integration and international development [1] - After the listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, creating a closed loop of "research and development - production - sales" [1][2] Group 3 - Dongyangguang Pharmaceutical is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, with a strategic focus on treating infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical aims to become a world-class innovative pharmaceutical company with a mature and well-circulated business model [2]

7月29日，东阳光（600673）长江药业完成最后一个交易日，正式启动港股市场首例"H股吸收合并私有 化+介绍上市"的创新资本运作。按计划，公司将于8月7日以"东阳光药"(股票代码：06887.HK)为主体登 陆港交所主板，开创中国创新药企资产证券化新范式。 东阳光药吸收合并港股上市子公司东阳光长江药业实现整体上市，即拟上市主体东阳光药提交H股上市 申请，向其控股子公司东阳光长江药业小股东发行H股，换取前述小股东所持上市公司东阳光长江药业 股份。吸收合并完成后，东阳光药再通过介绍方式实现上市。 业内人士指出，此举不仅打破了传统资本运作方式的时间壁垒，降低企业收购产生的资金摩擦成本，实 现了资源整合与资本升级衔接，还能有效保证股东权益，为产业整合与国际化发展提供了可借鉴范例， 也是积极响应国家"优化资本市场结构"决策部署的生动体现。 东阳光药相关负责人表示，赴港上市后，东阳光药将获得长线资本支持，并有望实现一体化驱动完成产 业升级，即东阳光药研发能力、研发管线将与东阳光长江药业覆盖全国的销售网络形成合力，形成"研 发——生产——销售"闭环，打造全球化运营平台。 资料显示，东阳光药是一家从事药物的研发、生产和商业 ...

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and is set to launch on the Hong Kong Stock Exchange, marking the first instance of "H-share absorption merger privatization + introduction listing" in the market [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on August 7, 2023, creating a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - This listing does not involve new share issuance or fundraising; instead, it involves the absorption merger of its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, allowing small shareholders to exchange their shares for H-shares [1] Group 2 - Industry insiders note that this approach breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The move is seen as a model for resource integration and capital upgrade, providing a reference for industrial consolidation and international development, aligning with national strategies to optimize capital market structures [1] - After the Hong Kong listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [1][2]

Core Viewpoint - Dongyangguang Pharmaceutical is on the verge of officially listing on the Hong Kong Stock Exchange after successfully passing the necessary shareholder votes for privatization and merger with its subsidiary Dongyangguang Changjiang Pharmaceutical [1][2]. Group 1: Listing Process - Dongyangguang Pharmaceutical announced its application for listing on June 29, and the final step involves the approval of the privatization and merger proposal, which received over 99% support from shareholders on July 21 [1][2]. - The company will commence trading on the Hong Kong Stock Exchange on August 7, 2023 [2]. Group 2: Merger and Share Exchange - The listing will occur through a unique method of "absorption merger + introduction," marking a first in the Hong Kong market [3]. - The share exchange ratio is set at 0.263614 shares of Dongyangguang Pharmaceutical for each share of Dongyangguang Changjiang Pharmaceutical, with the theoretical value of Dongyangguang Pharmaceutical's H-shares estimated between 67.04 HKD and 81.44 HKD by the end of 2024 [4]. Group 3: Special Dividend and Shareholder Benefits - Shareholders of Dongyangguang Changjiang Pharmaceutical will receive a special dividend of 1.50 HKD per share post-merger, with approximately 4.28 billion H-shares eligible for this dividend [4][6]. - The potential premium for minority shareholders, considering the privatization and special dividend, could exceed 40% since the stock price on June 27 was 14.90 HKD, while the estimated value during privatization is around 19.36 HKD [4][6]. Group 4: Growth Potential and Innovation - Dongyangguang Pharmaceutical has seen a stock price increase of over 70% year-to-date, indicating strong market performance [6]. - The company has developed a comprehensive R&D platform over 20 years, with 150 drugs available globally and over 100 in development, including 49 first-class innovative drugs with significant commercial potential [6][7]. - Notable drugs include Clifofitinib, with a peak sales potential of 1 billion USD, and another drug, Ifenidone, which shows promise in treating various conditions [7].

Core Viewpoint - Dongyangguang Pharmaceutical is set to become the first H-share company to undergo a merger and introduction listing, with its IPO application approved by the Hong Kong Stock Exchange, indicating significant advancements in technology, internationalization, and policy alignment [1] Group 1: Business Development - Dongyangguang's flagship product, Kewai, has generated substantial cash flow since its launch in 2006, with sales of Oseltamivir (including Kewai) maintaining the top position in the national market, accounting for 54.8% of the market share in 2024 [2][4] - The company's revenue from chronic disease treatment drugs has increased from 13.6% in 2022 to 26.6% in 2024, reflecting a strategic shift from reliance on flu medications to a diversified innovative pharmaceutical enterprise [4][6] Group 2: Innovation and R&D - Dongyangguang has established a robust R&D capability, focusing on innovative drugs since its inception, with advanced AI-driven models and a comprehensive R&D platform covering the entire lifecycle of chemical and biological drugs [6][8] - The company currently has 150 approved drugs globally and over 100 drugs in development, with several first-class innovative drugs already launched or in the application process in the Chinese market [7] Group 3: Internationalization Strategy - The company has signed a significant licensing agreement with Apollo in the UK worth $938 million, showcasing the international recognition of its drug portfolio [8] - Dongyangguang is one of the few companies capable of submitting applications to the US FDA and is expected to be the first to launch a long-acting insulin analog in the US without the need for Phase III clinical trials [8][9] Group 4: Market Position and Future Outlook - With the support of China's policies for innovative drug development, Dongyangguang is positioned as a leader in the global pharmaceutical market, leveraging its full-chain innovation capabilities to enhance R&D efficiency and international market access [9][11] - The company plans to integrate with Dongyangguang Changjiang Pharmaceutical to enhance its R&D, production, and commercialization capabilities, aiming for a successful listing on the Hong Kong Stock Exchange by August 2025 [11]